Transdermal rivastigmine for HIV-associated cognitive impairment: A randomized pilot study.

ABSTRACT:

Objective

To assess the efficacy and safety of transdermal rivastigmine for the treatment of HIV-associated cognitive impairment.

Methods

We recruited HIV-infected patients with cognitive impairment on stable antiretroviral therapy in a randomized controlled pilot trial with a 48-week follow-up. An additional assessment was held at 12 weeks. Participants received transdermal rivastigmine (9.5 mg daily), lithium (400 mg twice daily, titrated progressively), or remained in a control group (no new medication). The primary efficacy endpoint was change in a global cognitive score (NPZ-7). Secondary endpoints included change in specific cognitive measures, domains, and functional parameters. Safety covered the frequency of adverse events and changes in laboratory results.

Resul

SUBMITTER: Munoz-Moreno JA 

PROVIDER: S-EPMC5576750 | biostudies-literature | 2017

REPOSITORIES: biostudies-literature